% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{:885928,
author = {Ю. Скворцова, T. and Judov, Natalie and Plotkin,
M. and Stoffels, Gabriele and Galldiks, Norbert and
Красикова, Р. Н. and Langen, Karl-Josef},
title = {{T}he {R}ole of {R}adionuclide {D}iagnostic {M}ethods in
{N}euro-{O}ncology},
journal = {Vestnik rentgenologii i radiologii},
volume = {101},
number = {4},
issn = {0042-4676},
address = {Moskva [u.a.]},
publisher = {Medicina},
reportid = {FZJ-2020-04184},
pages = {221 - 234},
year = {2020},
abstract = {In recent years, positron emission tomography (PET) with
amino acid radiopharmaceuticals has assumed increasing
importance in the diagnosis of brain tumors and it has
already become an additional method of examination along
with magnetic resonance imaging (MRI) in many diagnostic
centers. The markers of somatostatin receptors seem to be
most promising for the PET diagnosis of meningiomas. PET
provides important additional information in the diagnosis
of brain changes of unknown origin and more accurate
information about tumor boundaries, which is necessary for
biopsy, neurosurgery, and radiation therapy. In addition,
labeled amino acid PET aids in the assessment of disease
prognosis, in the differentiation of continued tumor growth
from nonspecific therapeutic pathomorphism of the brain, and
in the evaluation of treatment efficiency at an earlier time
than is possible with MRI.},
cin = {INM-4 / INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-3-20090406},
pnm = {573 - Neuroimaging (POF3-573)},
pid = {G:(DE-HGF)POF3-573},
typ = {PUB:(DE-HGF)16},
doi = {10.20862/0042-4676-2020-101-4-221-234},
url = {https://juser.fz-juelich.de/record/885928},
}